Metopen (Methotrexate)

Methotrexate blocks dihydrofolate reductase, an enzyme needed to produce tetrahydrofolate. Without tetrahydrofolate, cells cannot synthesize purines and pyrimidines, leading to reduced DNA, RNA, and protein formation. This effect is most pronounced in fast‑dividing cells, such as activated immune cells and cancer cells, thereby providing immunosuppressive and antineoplastic actions.

The dose of Metopen is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Healthcare providers determine the appropriate amount and frequency, and patients should follow the prescriber’s instructions without altering the regimen.

Methotrexate is known to be teratogenic and is generally contraindicated during pregnancy. Women of child‑bearing potential should use effective contraception before, during, and after treatment. Limited data exist for breastfeeding, and the drug may pass into breast milk, so use is usually avoided unless the benefits outweigh the risks.

To request Metopen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and the necessary import documentation.

Compared with biologic DMARDs, methotrexate (Metopen) is a small‑molecule agent that is generally less expensive and administered via subcutaneous injection. It has a well‑established efficacy profile for rheumatoid arthritis and psoriasis, but may require more laboratory monitoring for hepatic and hematologic safety than some biologics.

Metopen should be stored at refrigerated temperatures between 2 °C and 8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If refrigeration is unavailable for a short period, follow the manufacturer’s guidance on temporary storage.

Metopen is supplied as a sterile solution for subcutaneous injection. The injection is typically given into the abdomen or thigh using a pre‑filled syringe or vial, following aseptic technique. Patients should be trained by a healthcare professional on proper injection site rotation and disposal of sharps.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to bone‑marrow suppression, and renal failure. Patients should be monitored regularly for liver enzymes, lung symptoms, blood counts, and kidney function, and any alarming signs should prompt immediate medical evaluation.

Metopen is contraindicated in individuals with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active infections, and in pregnant women. Caution is also advised for patients with pre‑existing blood disorders or those receiving other myelosuppressive therapies.